Abstract
Parkinson’s disease (PD) and dementia with Lewy bodies (DLB) are neurodegenerative disorders characterized by the misfolding and aggregation of alpha-synuclein (aSyn). Doxycycline, a tetracyclic antibiotic shows neuroprotective effects, initially proposed to be due to its anti-inflammatory properties. More recently, an additional mechanism by which doxycycline may exert its neuroprotective effects has been proposed as it has been shown that it inhibits amyloid aggregation. Here, we studied the effects of doxycycline on aSyn aggregation in vivo, in vitro and in a cell free system using real-time quaking induced conversion (RT-QuiC). Our results show that doxycycline decreases the number and size of aSyn aggregates in cells. In addition, doxycycline inhibits the aggregation and seeding of recombinant aSyn, and attenuates the production of mitochondrial-derived reactive oxygen species. Finally, we found doxycycline induces a cellular redistribution of the aggregates in an animal model of PD that is associated with a recovery of dopaminergic function. In summary, we provide strong evidence that doxycycline treatment may be an effective strategy against synucleinopathies.
Footnotes
↵* Co-senior authors, Email: Prof. Dr. Tiago F. Outeiro, Department of Experimental Neurodegeneration, University Medical Center Goettingen, 37073 Goettingen, Germany, Telephone: +495513913545, Email: tiago.outeiro{at}med.uni-goettingen.de or Dr. Nicolas Bizat, Institut du Cerveau et de la Moelle, Hôpital de la Pitié-Saplêtrière, 47, Bd de l’Hôpital, Paris F-75013, France, Telephone: +331 5727 4388, Email: nicolas.bizat{at}icm-institute.org
